Strainprint™ Closes USD $3 Million (Cdn.$3.8M) Series A Funding

TORONTOMay 8, 2018 /PRNewswire/ – StrainprintTM Technologies — the leader in cannabis data and analytics is pleased to announce the closing of a USD $3 Million (Cdn.$3.8 Million) non-brokered, Series A private placement. The round was led by strategic industry investor, Cesare Fazari, Chairman of Molecular Science Corp and seed investor of leading cannabis companies, Ample Organics and Hydropothecary. Mr. Fazari will also join Strainprint’s Board of Directors and will play an active role in strategic business development.  The round also includes a significant follow-on investment from NY-based, Core Strain Ltd., as well as participation from a number of Toronto-based capital funds.

Strainprint will use proceeds for talent acquisition and to rapidly expand sales and marketing of its disruptive Strainprint Analytics web platform across North America and into key international markets like Australia and Germany. The company will also continue to innovate its industry-leading outcomes-tracking mobile journal for patients with symptom-specific measurement protocols and ethics compliance, developed together with our world-class medical advisors.

Since February 2017, tens of thousands of medical cannabis patients have tracked over 500,000 medical records on Strainprint’s mobile patient journal, generating over 7 million data points on strain efficacy and patient use.  It is the largest and most granular longitudinal study of its kind and its growing by 25% per month. In addition to helping patients lead healthier lives, this medically validated data is helping to shape the entire cannabis industry by providing business intelligence, as well as treatment and product guidance for producers, retailers, clinicians, researchers, pharma, insurance and government.

“This funding round represents a key milestone for Strainprint that will allow us to capitalize on our first-mover advantage as the premier source of medical cannabis use data,” said Strainprint CEO, Andrew Muroff. “Amongst other initiatives, we plan to rapidly provision our team and SaaS products to serve international markets where imported Canadian cannabis is the primary source of available product.”

The Strainprint mobile app is available for free to patients on both iOS and Android, while web-based Strainprint Analytics is available by monthly subscription.

About StrainprintTM:
Founded in Toronto in 2016,StrainprintTM Technologies Ltd. is the leading demand-side cannabis data and analytics company, gathering real-time cannabis consumption and efficacy data on lab-verified strains, while providing enterprise business intelligence to the global cannabis industry. StrainprintTM data supports global cannabis research and provides advanced business intelligence to producers, retailers, medical practitioners, pharma, government and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted and all patient data is anonymized and at rest in Canada. Strainprint can be seamlessly embedded or integrated with most electronic medical records (EMR), seed2sale and Ecomm software systems.  The Strainprint App is free to patients and can be downloaded from both the iOS App and GooglePlay stores. www.strainprintanalytics.comwww.strainprint.cafacebooktwitterlinkedin

Strainprint™ Technologies Ltd. (“Strainprint”) Welcomes Three Leading Cannabinoid Physicians to its Board

Dr. Caroline MacCallum, Dr. Danial Schecter & Dr. Dean Elterman
Join Strainprint’s World-Class Medical Advisory Board

TORONTO, April 17, 2018 /CNW/ – Strainprint, the leader in cannabis data & analytics, is pleased to announce that Dr. Caroline MacCallum, Dr. Danial Schecter and Dr. Dean Elterman have joined its Board of Medical Advisors. Strainprint works closely with its medical advisors to support patients, enhance research and to advance the scientific understanding of cannabinoid therapy. With over 400,000 medical records and almost 7 million data points, and growing, Strainprint is the most trusted source for strain efficacy and patient use data. Dr. MacCallum and Dr. Schecter will jointly lead Strainprint’s Medical Advisory Board as Co-chairs and Dr. Elterman will focus on specific cannabinoid studies through the University Health Network.

Dr. Caroline MacCallum graduated from UBC Internal Medicine Residency in 2013. She practiced complex pain in a number of clinics and hospitals in Vancouver including, Vancouver General Hospital Pain & Addiction Service, Change Pain clinic and BC Women’s Complex Chronic Disease Program. She is also clinical instructor in the UBC Department of Medicine, guest lecturer and preceptor for UBC Faculty of Pharmaceutical Sciences Program and the Medical Director for Greenleaf Medical Clinic. Dr. MacCallum has created online cannabis courses, CMEs, and preceptorships for physicians. She works with national committees to create cannabis guidelines and safe prescribing practices, as well as writing cannabis policy for hospitals and drug benefit plan coverage. She is qualified as a medical cannabis expert and has testified in arbitration. Her research interests include: cannabis for the treatment of complex medical conditions; cannabis for opioid and polypharmacy reduction; as well as cannabis and impairment.

Dr. Danial Schecter is co-founder of the Cannabinoid Medical Clinic (CMClinic) and a practicing family physician. After working alongside some of Canada’s leading researchers in the field of medical marijuana, Dr. Schecter developed a strong interest in the therapeutic use of cannabinoids. As a recognized medical expert in the field of prescription cannabinoids and medical marijuana, Dr. Schecter has spoken at over 100 conferences both nationally and internationally and has developed educational programs on this subject. Dr. Schecter sits on a variety of cannabis advisory boards and consults internationally to key industry stakeholders in Australia, Latin America and Europe. In addition to cannabinoid medicine, Dr. Schecter’s clinical interests include delivering a high standard of care to at-risk elderly and palliative care patients, prompting him to establish his own house-calls service in Georgian Bay, ON. Dr. Schecter completed a fellowship in Hospital Medicine and is an active hospitalist at the Royal Victoria Regional Health Centre in Barrie, ON.

Dr. Dean S. Elterman completed his medical degree followed by residency in urologic surgery at the University of Toronto. He has a Masters in Clinical Epidemiology and Health Services Research from Cornell and completed a 2-year fellowship at Memorial Sloan-Kettering Cancer Center and New York Presbyterian Hospital/Weill Cornell Medical College in New York City. Dr. Elterman is an attending surgeon at UHN (University Health Network) and an Assistant Urology Professor in the Department of Surgery at University of Toronto. He is the Medical Director of the Prostate Cancer Rehabilitation Clinic at Princess Margaret Hospital Cancer Centre and a clinician Investigator in the Krembil Research Institute at Toronto Western hospital. Dr. Elterman is chair of the medical advisory board for Molecular Science Corp. and has a particular interest in the study of cannabis and cannabinoid therapy.

“All three of our new medical advisors are leaders in their respective fields and devoted to advancing cannabinoid research and therapy. We are so proud to be working with these great physicians who will help us to shape both the medical and recreational cannabis industries with real-world, real-time, medical-grade data,” said Strainprint CEO, Andrew Muroff.

Read More about Strainprint Advisors

About Strainprint™:
Founded in Toronto in 2016, Strainprint™ Technologies Ltd. is the leading demand-side cannabis data and analytics company, featuring medically validated cannabis consumption and efficacy data on lab-verified strains. StrainprintTM data supports global cannabis research and provides advanced, real-time business intelligence and treatment guidance to producers, retailers, medical practitioners, pharma, government and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted encrypted and all patient data is completely anonymized and at rest in Canada. Strainprint can be seamlessly integrated with most electronic medical records (EMR), seed2sale and Ecomm software systems. Strainprint Analytics is accessed by customer subscription. The Strainprint App is free to patients and can be downloaded for both iOS and Android devices. facebook, twitter, linkedin

For further information: Media Contact: Jessica Moran, Strainprint™ Technologies Ltd.,, 519-494-5379

Strainprint Featured in Direct Cannabis Network: Strainprint ™ App,Tracking Your Cannabis Intake


Whether you are a medical cannabis patient or a recreational user, tracking your cannabis consumption habits are not only essential but also largely beneficial. Some people find it helpful to chronical their treatment journey in a paper-based journal but often find it inconvenient to capture each interaction and thus have an inaccurate record of useful treatment interactions and outcomes data. For those patients that are looking to learn more about what works best (medically or recreationally), there is an innovative mobile app that provides guidance – Strainprint™.

To read more about Strainprint’s Feature in Direct Cannabis Network click here.